



## Stereospecific synthesis of $\alpha,\omega$ -*cis*- and $\alpha,\omega$ -*trans*-disubstituted oxepanes

Ryuji Matsumura,<sup>a</sup> Toshio Suzuki,<sup>a,\*</sup> Kohki Sato,<sup>a</sup> Takashi Inotsume,<sup>b</sup>  
Hisahiro Hagiwara,<sup>a</sup> Takashi Hoshi,<sup>b</sup> Vijayendra P. Kamat<sup>b</sup> and Masayoshi Ando<sup>b</sup>

<sup>a</sup>Graduate School of Science and Technology, Niigata University, 2-nocho, Ikarashi, Niigata 950-2181, Japan

<sup>b</sup>Faculty of Engineering, Niigata University, 2-nocho, Ikarashi, Niigata 950-2181, Japan

Received 13 July 2000; revised 3 August 2000; accepted 4 August 2000

### Abstract

An efficient and versatile method for the stereospecific construction of  $\alpha,\omega$ -*cis*- and  $\alpha,\omega$ -*trans*-disubstituted oxepane skeletons is described. Cyclization of the hydroxy epoxides promoted by a  $(\text{Bu}_3\text{Sn})_2\text{O}/\text{Zn}(\text{OTf})_2$  system proceeded via an  $\text{S}_{\text{N}}2$  process and *exo* mode selectivity regardless of the configuration of the hydroxyl and the epoxy groups to provide the corresponding oxepanes in excellent yields. © 2000 Elsevier Science Ltd. All rights reserved.

**Keywords:** cyclization; epoxides; oxepanes; regioselection.

Oxepanes constitute a prominent structural feature of many natural products, represented by (+)-isolaurepinnacin (**1**)<sup>1</sup> and (+)-regioloxepane A (**2**)<sup>2</sup> (Fig. 1), isolated from the marine algae belonging to a variety of the *Laurencia* species. Much attention has been focused on efficient approaches toward this system.<sup>3</sup> In particular, the stereoselective introduction of alkyl substituents into the  $\alpha$ - and  $\omega$ -position of a cyclic ether possessing *cis*- or *trans*-orientation is an important synthetic goal. While some efficient methods toward stereoselective synthesis of  $\alpha,\omega$ -*cis*-oxepanes were developed,<sup>4</sup> few methods have been found for the  $\alpha,\omega$ -*trans*-oxepane system.<sup>4f,m,5</sup> We described an efficient protocol for the synthesis of oxepane via intramolecular opening of hydroxy epoxides promoted by a  $(\text{Bu}_3\text{Sn})_2\text{O}/\text{Lewis acid}$  system in the preceding article; this reaction proceeded via an  $\text{S}_{\text{N}}2$  process and *exo* mode regardless of the geometry of




Figure 1.

\* Corresponding author. Tel/fax: +81-25-262-6780; e-mail: suzuki@eng.niigata-u.ac.jp


the epoxy group. We initiated the present work in an effort to explore the possibility of applying this methodology to the stereospecific construction of  $\alpha,\omega$ -*cis*- and  $\alpha,\omega$ -*trans*-oxepane skeletal systems.

The requisite key intermediate, hydroxy *trans*-epoxide **7** leading to  $\alpha,\omega$ -*cis*-oxepane, was prepared stereoselectively from the corresponding acetylene derivative **4**<sup>6</sup> and bromoepoxide **6**. The other intermediate **8** required for the preparation of the *trans*-analogue was obtained from the epoxy alcohol **7** via a Mitsunobu reaction<sup>7</sup> (Scheme 1).




Scheme 1. *Reagents and conditions*: (a) TBSCl, NaH, THF, 100%; (b) TBHP, (+)-DET, Ti(O<sup>*i*</sup>-Pr)<sub>4</sub>, 4AMS, CH<sub>2</sub>Cl<sub>2</sub>, 93%, 89% ee; (c) TsCl, TEA, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 97%; (d) LiBr, DMF, 50°C, 94%; (e) *n*-BuLi, HMPA, THF, -30°C; (f) TBAF, THF, 52% (two steps); (g) H<sub>2</sub>, Pd-C, AcOEt, 78%; (h) DEAD, PPh<sub>3</sub>, *p*-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, THF, 98%; (i) K<sub>2</sub>CO<sub>3</sub>, MeOH, 96%

With the desired hydroxy *trans*-epoxides **7** and **8** in hand, we then proceeded with the stereospecific cyclization protocol. The tin ether prepared from **7** by reacting it with (Bu<sub>3</sub>Sn)<sub>2</sub>O (0.6 equiv.) in refluxing toluene<sup>8</sup> was treated with Zn(OTf)<sub>2</sub> (0.4 equiv.) at 90°C. Under the conditions, the cyclization reaction proceeded smoothly to afford the corresponding  $\alpha,\omega$ -*cis*-oxepane **9** in 85% yield as the sole cyclic product. Similarly, the cyclization of the other isomer **8** proceeded with the same reactivity under the same reaction conditions to give the corresponding  $\alpha,\omega$ -*trans*-derivative **10** in 80% yield. The relative stereochemistry of the cyclized products **9** and **10** at the  $\alpha,\omega$ -positions with respect to each other was ascertained by NOE experiments. Further, the  $\alpha,\omega$ -*cis*-oxepane **9** was converted to its epoxide **11** to explore its NOE correlations in view of the overlapping of  $\alpha$ -H and  $\omega$ -H signals in the <sup>1</sup>H NMR spectrum (Scheme 2). It may be noted that the ready formation of terminal epoxide **11** from **9** confirms the earlier regioselective *exo* mode cyclization of **7** to the  $\alpha,\omega$ -*cis*-oxepane derivative **9**.




Scheme 2. *Reagents and conditions*: (a) MsCl, TEA, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 99%; (b) DDQ, CH<sub>2</sub>Cl<sub>2</sub>, H<sub>2</sub>O; (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, CH<sub>2</sub>Cl<sub>2</sub>, 85% (two steps)

Next, we turned our investigation to probe the reactivity of *cis*-epoxy substrates under the same reaction conditions. The desired cyclization precursors **15** and **16** were prepared by the protocol shown in Scheme 3. Epoxide **13** derived from 2,3-*O*-isopropylidene-D-threitol **12** was coupled with the acetylene derivative **4** by following the Yamaguchi method.<sup>9</sup> The resulting intermediate **14** was transformed to the hydroxy *cis*-epoxides **15** and **16** via standard procedures. Repeating the above-mentioned cyclization protocol on *cis*-epoxides **15** and **16** under identical reaction conditions provided, respectively, the corresponding  $\alpha,\omega$ -*cis*-oxepane **17** (68%) and its *trans*-isomer **19** (79%). It may also be noted that compared to the *trans*-epoxides **7** and **8**, there is a decrease in the reactivity of *cis*-epoxides **15** and **16**, and this property is reflected in the isolation of rearranged ketones **18** and **20** as minor products during the cyclization reaction (Scheme 4).



Scheme 3. *Reagents and conditions*: (a) MPMCl, NaH, DMF; (b) TsCl, TEA, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 72% (two steps); (c) Amberlyst 15, MeOH; (d) K<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, MeOH, 52% (two steps); (e) **4**, *n*-BuLi, BF<sub>3</sub>·OEt<sub>2</sub>, THF, -78°C, 60%; (f) H<sub>2</sub>, Pd-C, AcOEt, 78%; (g) MsCl, TEA, DMAP, CH<sub>2</sub>Cl<sub>2</sub>; (h) TBAF, THF, 97% (two steps); (i) DEAD, PPh<sub>3</sub>, *p*-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, THF, 95%; (j) K<sub>2</sub>CO<sub>3</sub>, MeOH, 95%



Scheme 4.

In conclusion, a highly efficient methodology for the stereospecific construction of  $\alpha,\omega$ -*cis*- and  $\alpha,\omega$ -*trans*-oxepanes, the fundamental structural unit of several important bioactive marine natural products, has been developed. Interestingly, the cyclization reaction proceeded via an S<sub>N</sub>2 process and *exo* mode selectivity and independently of the hydroxyl and epoxide groups configuration in the substrate. Furthermore, the newly generated asymmetric centers are stereospecifically induced in the product molecule. The oxepane derivatives **9**, **10**, **17** and **19**

inherited the requisite carbon skeleton and stereochemistry for its application to the synthesis of natural products (+)-isolaurepinnacin (**1**) and (+)-rogioloxepan A (**2**). Further efforts in this direction are in progress in our laboratory.

### Acknowledgements

This work was financially supported in part by the Grant-in-Aid for Scientific Research on Priority Area No. 08245101 from the Ministry of Education, Science, Sports and Culture of the Japanese Government.

### References

1. Fukuzawa, A.; Masamune, T. *Tetrahedron Lett.* **1981**, *41*, 4081–4084.
2. Guella, G.; Mancini, I.; Chiasera, G.; Pietra, F. *Helv. Chim. Acta* **1992**, *75*, 310–322.
3. For a review of synthetic investigation in this area, see: Albizzati, K.; Martin, V. A.; Agharahimi, M. R.; Stolze, D. A. In *Bioorganic Marine Chemistry*; Scheuer, P. J., Ed.; Springer-Verlag: Berlin, 1992; Vol. 6, pp. 69–84.
4. (a) Hori, N.; Matsukura, H.; Nakata, T. *Org. Lett.* **1999**, *1*, 1099–1101. (b) Mori, Y.; Yaegashi, K.; Furukawa, H. *J. Am. Chem. Soc.* **1997**, *119*, 4557–4558. (c) Isobe, M.; Hosokawa, S.; Kira, K. *Chem. Lett.* **1996**, 473–474. (d) Nakata, T.; Nomura, S.; Matsukura, H.; Morimoto, M.; *Tetrahedron Lett.* **1996**, *37*, 217–220. (e) Oishi, T.; Shoji, M.; Maeda, K.; Kumahara, N.; Hirama, M. *Synlett* **1996**, 1165–1167. (f) Palazón, J. M.; Martín, V. S. *Tetrahedron Lett.* **1995**, *36*, 3549–3552. (g) Nicolaou, K. C.; Hwang, C.-K.; Duggan, M. E.; Nugiel, D. A.; Abe, Y.; Reddy, K. B.; DeFrees, S. A.; Reddy, D. R.; Awartani, R. A.; Rutjes, F. P. J. T.; Theodorakis, E. A. *J. Am. Chem. Soc.* **1995**, *117*, 10227–10238. (h) Kadota, I.; Matsukawa, Y.; Yamamoto, Y. *J. Chem. Soc., Chem. Commun.* **1993**, 1638–1641. (i) Carling, R. W.; Clark, J. S.; Holmes, A. B. *J. Chem. Soc., Perkin Trans. 1* **1992**, 83–94. (j) Feng, F.; Murai, A. *Chem. Lett.* **1992**, 1587–1590. (k) Davies, M. J.; Moody, C. J. *J. Chem. Soc., Perkin Trans. 1* **1991**, 9–12. (l) Yamada, J.; Asano, T.; Kadota, I.; Yamamoto, Y. *J. Org. Chem.* **1990**, *50*, 6066–6068. (m) Kotsuki, H.; Ushio, Y.; Kadota, I.; Ochi, M. *J. Org. Chem.* **1989**, *54*, 5153–5161. (n) Castañeda, A.; Kucera, D. J.; Overman, L. E. *J. Org. Chem.* **1989**, *54*, 5698–5707.
5. (a) Mujica, M. T.; Afonso, M. M.; Galindo, A.; Palenzuela, J. A. *Tetrahedron Lett.* **1994**, *35*, 3401–3404. (b) Davies, M. J.; Moody, C. J.; Taylor, R. J. *Synlett* **1990**, 93–96.
6. Takano, S.; Sekiguchi, Y.; Ogasawara, K. *J. Chem. Soc., Chem. Commun.* **1987**, 555–557.
7. (a) Mitsunobu, O. *Synthesis*, **1981**, 1–28. (b) Martin, S. F.; Dodge, J. A. *Tetrahedron Lett.* **1991**, *32*, 3017–3020.
8. Ogawa, T.; Matsui, M. *Carbohydr. Res.* **1977**, *56*, C1–C6.
9. Yamaguchi, M.; Hirano, I. *Tetrahedron Lett.* **1983**, *24*, 391–394.